Coverage guidelines for BRCA1 and BRCA2

The safety and effectiveness of simultaneous testing for inherited BRCA1 and BRCA2 mutations have been established. It may be considered a useful diagnostic option when indicated for individuals at high risk of breast or ovarian cancer. Testing for genomic rearrangements of the BRCA1 and BRCA2 genes (e.g., BART testing) may be considered established in patients who meet criteria for BRCA1 and BRCA2 testing and whose testing for point mutations is negative and has one of the following: • Three or more family members (one lineage) affected with breast, ovarian, fallopian tube or primary peritoneal cancer. • A risk of a BRCA mutation of at least 10 percent.